Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

United Therapeutics (UTHR) Cash & Equivalents (2016 - 2025)

United Therapeutics (UTHR) has disclosed Cash & Equivalents for 17 consecutive years, with $1.6 billion as the latest value for Q4 2025.

  • Quarterly Cash & Equivalents fell 8.25% to $1.6 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.6 billion through Dec 2025, down 8.25% year-over-year, with the annual reading at $1.6 billion for FY2025, 8.25% down from the prior year.
  • Cash & Equivalents hit $1.6 billion in Q4 2025 for United Therapeutics, up from $1.3 billion in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $1.9 billion in Q1 2025 to a low of $795.2 million in Q2 2022.
  • Historically, Cash & Equivalents has averaged $1.2 billion across 5 years, with a median of $1.1 billion in 2023.
  • Biggest five-year swings in Cash & Equivalents: decreased 15.6% in 2022 and later surged 51.81% in 2025.
  • Year by year, Cash & Equivalents stood at $894.8 million in 2021, then grew by 7.42% to $961.2 million in 2022, then increased by 25.65% to $1.2 billion in 2023, then surged by 40.53% to $1.7 billion in 2024, then fell by 8.25% to $1.6 billion in 2025.
  • Business Quant data shows Cash & Equivalents for UTHR at $1.6 billion in Q4 2025, $1.3 billion in Q3 2025, and $1.6 billion in Q2 2025.